middle.news
Percheron Halts Avicursen Trial, Raises $14.85M to Pivot Pipeline Strategy
8:41am on Friday 31st of January, 2025 AEDT
•
Biotechnology
Read Story
Percheron Halts Avicursen Trial, Raises $14.85M to Pivot Pipeline Strategy
8:41am on Friday 31st of January, 2025 AEDT
Key Points
Phase IIb avicursen trial in Duchenne muscular dystrophy terminated due to lack of efficacy
Company raised $13 million via institutional placement and $1.85 million through Share Purchase Plan
Strategic review underway to identify new pipeline opportunities with shareholder value focus
US OTCQB uplisting completed, ticker changed to PERCF
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Percheron Therapeutics (ASX:PER)
OPEN ARTICLE